Guggenheim initiated coverage of C4 Therapeutics (CCCC) with a Buy rating and $8 price target The firm believes investors are overlooking the clinical profile differentiation established by C4 and the market “whitespace” available in the myeloma treatment paradigm. The company’s cemsidomide could have a wider therapeutic index and active dose range relative to Bristol-Myer’s (BMY) mezigdomide, with better activity in a more relevant late-line myeloma population, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC: